jobs.jnj.com/en/jobs/
Skip to content
✕
Internet Explorer is no longer supported by this website.
For optimal browsing we recommend using
Chrome
,
Firefox
or
Safari
.
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Menu
Menu
Toggle Menu
Change Country
Our Businesses
Our Stories
Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage
Our Company
About J&J
Our Credo
Our Leadership Team
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health and Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Products
MedTech
Pharmaceutical Products
Suppliers
Responsible Supply Base
Supplier-Enabled Innovation
Supplier Resources
Careers
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Media Center
Investors
2023 Annual Meeting of Shareholders
Corporate Governance
Quarterly Results
SEC Filings
News Releases
Pharmaceutical Pipeline
2022 Janssen Transparency Report
2022 Health for Humanity Report
ESG Resources
Stock Information
Webcasts & Presentations
Investor Fact Sheet
Our Societal Impact
Global Community Impact
Global Public Health
Global Environmental Sustainability
Close Countries Menu
Explore more Johnson & Johnson sites:
China
France
Germany
India
Japan
Russia
Switzerland
German
English
French
United Kingdom
United States
Search input
Dictate search request
Empty search box
Recently Viewed
Share
Latest COVID-19 News
Latest News
March 08, 2022
Johnson & Johnson Announces Landmark Agreement to Enable its COVID-19 Vaccine to be Manufactured and Made Available by an African Company for People Living in Africa
Innovation
January 06, 2022
Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States
Innovation
December 30, 2021
Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
Innovation
December 15, 2021
Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
Innovation
December 09, 2021
World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster
Innovation
December 05, 2021
Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses
Innovation
November 24, 2021
Johnson & Johnson COVID-19 Vaccine Fully Approved by Health Canada to Prevent COVID-19 in Individuals 18 years and Older
Our Company
November 10, 2021
Johnson & Johnson Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine for the World’s Most Vulnerable People through Novel Humanitarian Buffer
October 21, 2021
U.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson COVID-19 Vaccine as a Booster for All Eligible Individuals Who Receive Authorized COVID-19 Vaccines
October 20, 2021
Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
Media Statement
October 18, 2021
17 Million Doses of Johnson & Johnson COVID-19 Vaccine to be Donated to African Union Countries
Innovation
October 15, 2021
Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
Innovation
October 05, 2021
Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine
Our Company
September 28, 2021
Johnson & Johnson Celebrates COVID-19 Vaccine Science Superheroes
Innovation
September 21, 2021
Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
Our Company
August 25, 2021
Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
Media Statement
July 28, 2021
Johnson & Johnson Statement on U.S. FDA Approval of Shelf Life Extension for Company’s COVID-19 Vaccine
Media Statement
July 14, 2021
Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in
New England Journal of Medicine
Our Company
July 09, 2021
Johnson & Johnson Statement on U.S. Government Donations of Company’s COVID-19 Vaccine
Our Company
July 01, 2021
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
Our Company
April 23, 2021
Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision
Our Company
April 20, 2021
Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) Review
EMA Confirms Overall Benefit-Risk Profile Remains Positive
Our Company
April 02, 2021
Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents
Our Company
March 29, 2021
Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company’s COVID-19 Vaccine Candidate
Our Company
March 12, 2021
Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
Our Company
March 11, 2021
Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission
Our Company
March 11, 2021
Johnson & Johnson Announces its Single-Shot COVID-19 Vaccine Candidate Receives Positive CHMP Opinion
Our Company
March 05, 2021
Johnson & Johnson COVID-19 Vaccine Granted Authorization under Interim Order by Health Canada For Emergency Use
Our Company
February 28, 2021
Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
October 20, 2021
Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
Our Company
February 26, 2021
Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
Our Company
February 19, 2021
Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
Our Company
February 16, 2021
Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
Innovation
February 04, 2021
Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
Our Company
January 29, 2021
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
Our Company
January 13, 2021
Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in
New England Journal of Medicine
Our Company
December 18, 2020
Johnson & Johnson Announces Agreement in Principle with Gavi to Supply Janssen’s COVID-19 Vaccine Candidate
to Lower-Income Countries in 2021
Our Company
December 17, 2020
Johnson & Johnson Announces Its First Phase 3 COVID-19 Vaccine Trial ENSEMBLE is Fully Enrolled
Our Company
December 01, 2020
Johnson & Johnson Announces the Initiation of a Rolling Submission for its Single-dose Janssen COVID-19 Vaccine Candidate with Health Canada
Our Company
October 23, 2020
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
Latest News
September 30, 2020
Life Science Companies and the Bill & Melinda Gates Foundation: Commitments to Expanded Global Access for COVID-19 Diagnostics, Therapeutics, and Vaccines
Our Company
September 25, 2020
(This statement was updated on October 4, 2020 to include additional information)
Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate
Our Company
September 23, 2020
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
Our Company
September 08, 2020
Biopharma Leaders Unite To Stand With Science
Our Company
September 03, 2020
Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies
Our Company
August 31, 2020
Johnson & Johnson Announces Agreement in Principle with Government of Canada to Supply its COVID-19 Vaccine Candidate
Our Company
August 14, 2020
Johnson & Johnson Announces Collaboration in Principle with the United Kingdom on Additional Phase 3 Study and Agreement to Supply its COVID-19 Vaccine Candidate
Our Company
August 05, 2020
Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
Our Company
July 30, 2020
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies
Our Company
June 10, 2020
Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July
Our Company
April 23, 2020
Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company’s Goal to Supply More Than One Billion Vaccine Doses Globally
Innovation
April 23, 2020
Global Advocacy and Communications Effort Launched to Drive Action Against COVID-19 and Stop Future Pandemics
Our Company
March 30, 2020
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
Our Company
March 16, 2020
Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2
Our Company
March 13, 2020
Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development
Innovation
February 18, 2020
Johnson & Johnson to Expand Partnership with U.S. Department of Health & Human Services to Accelerate the Discovery of Potential COVID-19 Treatments
Our Company
January 29, 2020
Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat
Learn how we're tackling the world's toughest health challenges
Learn more
Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue
